NewAmsterdam Pharma (NAMS) Cash from Financing Activities (2023 - 2026)

NewAmsterdam Pharma has reported Cash from Financing Activities for 4 years, with the latest figure at $11.1 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 69.73% year-over-year to $11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.1 million (down 92.72% YoY) and the FY2025 annual result came in at $29.5 million, down 95.52% from the prior year.
• Cash from Financing Activities fell to $11.1 million in Q1 2026 per NAMS's latest filing, from $13.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $456.6 million in Q4 2024 and troughed at $58000.0 in Q3 2024.
• A 4-year average of $59.1 million and a median of $6.1 million in 2023 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 10058.62% in 2025, down 97.0% in 2025.
• Over 4 years, Cash from Financing Activities stood at $186000.0 in 2023, then soared by 245389.78% to $456.6 million in 2024, then tumbled by 97.0% to $13.7 million in 2025, then fell by 19.14% to $11.1 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $11.1 million, $13.7 million, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.